Neuroprotective strategies targeting apoptotic and necrotic cell death for stroke
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
It has been a major challenge to develop effective therapeutics for stroke, a leading cause of death and serious debilitation. Intensive research in the past 15 years have implicated many regulators and the related mechanisms by which neuronal cell death is regulated. It is now clear that even a brief ischemic stroke may trigger complex cellular events that lead to both apoptotic and necrotic neuronal cell death in a progressive manner. Although efforts at developing specific chemical inhibitors for validated targets have been successful for in vitro enzymatic assays, the development of some of such inhibitors into human therapy has been often hindered by their in vivo bioavailability profile. Considerations for the ability to chemically target a cellular mechanism in manner compatible with disease targets in vivo might be emphasized early in the development process by putting a priority on identifying key targets that can be effectively targeted chemically. Thorough interrogation of cellular pathways by saturation chemical genetics may provide a novel strategy to identify multiple key molecular entities that can be targeted chemically in order to select a target suitable for the treatment of intended human diseases such as stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury
Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G. D., Mitchison, T. J., Moskowitz, M. A., & Yuan, J. (2005) · Nature Chemical Biology · doi:10.1038/nchembio711 · Cited by 3,068 · cited 2×
“A family of small molecule inhibitors of necroptosis, termed necrostatins, were identified using high throughput cell-based screens [51, 52, 55, 56].”
BackgroundSelf-citationSP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558 · cited 1×
“reversible ATP competitive JNK inhibitor [26], diminished JNK activity and infarct volume after transient focal ischemia in mice [27] and global ischemia/reperfusion in the vulnerable hippocampal CA1 subregion in rats [28].”
BackgroundIdentification of RIP1 kinase as a specific cellular target of necrostatins
Degterev, A., Hitomi, J., Germscheid, M., Ch'en, I. L., Korkina, O., Teng, X., Abbott, D., Cuny, G. D., Yuan, C., Wagner, G., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.83 · Cited by 2,059 · cited 4×
“A family of small molecule inhibitors of necroptosis, termed necrostatins, were identified using high throughput cell-based screens [51, 52, 55, 56].”
BackgroundInfluentialSelf-citationMediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor
Yu, S.-W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., & Dawson, V. L. (2002) · Science · doi:10.1126/science.1072221 · Cited by 1,826 · cited 2×
“In this regard, the activation of PARP-1 has been shown to mediate mitochondrial damage and the release of AIF from the mitochondria to induce necrotic cell death [41].”
BackgroundThe Mystery and Magic of Glia: A Perspective on Their Roles in Health and Disease
Barres, B. A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.013 · Cited by 1,352 · cited 1×
“Glia have been increasingly recognized to play an important role in neuronal function [18]; however, very little is currently known about cell death mechanisms of glia.”
BackgroundNitric Oxide Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity
Zhang, J., Dawson, V. L., Dawson, T. M., & Snyder, S. H. (1994) · Science · doi:10.1126/science.8080500 · Cited by 1,118
Hitomi, J., Christofferson, D. E., Ng, A., Yao, J., Degterev, A., Xavier, R. J., & Yuan, J. (2008) · Cell · doi:10.1016/j.cell.2008.10.044 · Cited by 989
Self-citationA peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658
Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke
Martin-Villalba, A., Hahne, M., Kleber, S., Vogel, J., Falk, W., Schenkel, J., & Krammer, P. H. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400882 · Cited by 209 · cited 1×
“FasL and TNFa may act coordinately in mediating ischemic brain injury as mice that are doubly deficient for both TNFa (tnf-/-) or FasL (gld) are protected against brain ischemia [54].”
Background
Cited by
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
Pathophysiology, treatment, and animal and cellular models of human ischemic stroke
Woodruff, T. M., Thundyil, J., Tang, S.-C., Sobey, C. G., Taylor, S. M., & Arumugam, T. V. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-11 · Cited by 598
Favaloro, B., Allocati, N., Graziano, V., Di Ilio, C., & De Laurenzi, V. (2012) · Aging · doi:10.18632/aging.100459 · Cited by 585
Deb, P., Sharma, S., & Hassan, K. M. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2009.12.001 · Cited by 562
Early Brain Injury, an Evolving Frontier in Subarachnoid Hemorrhage Research
Fujii, M., Yan, J., Rolland, W. B., Soejima, Y., Caner, B., & Zhang, J. H. (2013) · Translational Stroke Research · doi:10.1007/s12975-013-0257-2 · Cited by 493
Metadata
- Authors
- Yuan, J.
- Venue
- Apoptosis
- Published
- 2009-01-10
- Volume
- 14
- Issue
- 4
- Pages
- 469-477
- ISSN
- 1360-8185 (ISSN-L)
- 1573-675X
- OpenAlex
- W1989654240
- Cited by
- 223
- References
- 10
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.